Sort
82,697 grants matching “vaccine development”
Studies of Receptor Interactions and Effects of Alarmins
$1,327,663Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Development of an H2O2-Inactivated Dengue Virus Vaccine
$1,327,554Mark K Slifka · Oregon Health & Science University · R01 · FY2012 · AI
Cancer Vaccines and Immunotherapy
$1,327,187Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo
$1,327,040David B. Weiner · Wistar Institute · U19 · FY2024 · AI
Glycolipid Presentation by CD1d
$1,326,316Albert S. Bendelac · University Of Chicago · P01 · FY2011 · AI
Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity
$1,326,308James B McLachlan · Tulane University Of Louisiana · R01 · FY2025 · AI
Pediatric Clinical Research Scholar Program - Washington
$1,325,793Children'S Research Institute · K12 · FY2005 · RR
INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCH: PEDIATRIC RESEARCH
$1,325,692Daniel Ernest Ford · Johns Hopkins University · UL1 · FY2007 · RR
A prospective study of critical environmental exposures in formative early life that impact lifelong health in rural US children: the New Hampshire Birth Cohort Study
$1,325,423Margaret Rita Karagas · Dartmouth College · UG3 · FY2016 · OD
Does repeated influenza vaccination constrain influenza immune responses and protection?
$1,325,203Sheena G Sullivan · University Of Melbourne · R01 · FY2022 · AI
IGF::OT::IGF SUPPORT FOR HPV16L1/RG1 CHIMERIC VIRUS-LIKE PARTICLE VACCINE CLINICAL DEVELOPMENT TASKS 1&2 PP: 9/25/2015 TO 9/24/2018
$1,325,083Alexander Lyubimov · University Of Illinois At Urbana-Champaign · N01 · FY2015 · CA
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,324,787Jose Ribeiro · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
$1,324,786Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI
Cardiac Transplantation in Infancy
$1,324,773Jeffrey L Platt · University Of Michigan At Ann Arbor · P01 · FY2009 · HL
VACCINE AND TREATMENT EVALUATION UNIT: CONCEPT AND PROTOCOL DEVELOPMENT
$1,324,403Robert Frenck · Cincinnati Childrens Hosp Med Ctr · N01 · FY2017 · AI
Immunity to Pulmonary Infections
$1,324,096Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Glycolipid Presentation by CD1d
$1,324,025Albert S. Bendelac · University Of Chicago · P01 · FY2012 · AI
Transporting Stable RNA Across the Blood-Brain Barrier for On-Demand Translation
$1,323,950Jessica Marie Larsen · Clemson University · DP2 · FY2025 · NS
Task X3: Production and Testing of Conjugate Cholera Vaccine
$1,323,948James Richardson · Advanced Bioscience Laboratories, Inc. · N01 · FY2014 · AI
Malaria Vaccine: AMA1-C1
$1,323,730Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Malaria Vaccine: Pfs25-Pvs25
$1,323,730Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2010 · AI
Therapeutic evaluation in ovarian and breast cancer GEMGDA models
$1,323,540Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Gut Homing Cells in SIV infection
$1,323,534Aftab A. Ansari · Emory University · R01 · FY2012 · AI
Development of an Adhesin-Toxoid Chimera Vaccine for Enterotoxigenic E. coli
$1,323,145Stephen J Savarino · Henry M. Jackson Fdn For The Adv Mil/Med · U01 · FY2009 · AI
Prevention Umbrella for MSM in the Americas
$1,323,041Susan Buchbinder · Public Health Foundation Enterprises · R01 · FY2011 · AI